I can help, but I don’t have live access to current news right now. Based on the latest available summaries I have, “Pompe” news typically refers to Pompe disease updates or companies/organizations named Pompe. If you meant Pompe disease news, here are common recent themes you might expect to see:
- New therapies and trial results for Pompe disease, including enzyme replacement therapies and gene therapies, with updates on FDA or EMA status.
- Regulatory approvals or label expansions for existing treatments (e.g., Nexviazyme, avalglucosidase alfa) and any new combination therapies under development.
- Clinical trial activity, including Phase 2/3 results for oral or substrate reduction therapies, and patient advocacy events.
- Real-world evidence and patient impact stories from WORLDSymposium or similar conferences.
If you can specify which “Pompe” topic you want (e.g., Pompe disease therapies, a company named Pompe, or a particular geographic region), I can fetch the latest details and summarize with citations. I can also set up a quick news brief or a short list of the top developments with dates and sources if you’d like.
Sources
pompe Latest Breaking News, Pictures, Videos, and Special Reports from The Economic Times. pompe Blogs, Comments and Archive News on Economictimes.com
economictimes.indiatimes.comGet the latest news on Pompe disease, its causes, symptoms, diagnosis, and treatments. Hear patient and caregiver voices from our growing Pompe community.
pompediseasenews.comWelcome to Pompeandyou.com, an educational community that provides information and resources to help you along your journey with Pompe disease.
pompeandyou.comSpark Therapeutics Stops Its Pompe Program The IPA has been informed that Spark Therapeutics has realigned its portfolio and made the difficult decision to stop its... Author: IPA News July 13, 2024 Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union Amicus Therapeutics announces that the European Commission (EC) has granted approval for Opfolda® (miglustat), an enzyme stabilizer of cipaglucosidase alfa, an...
worldpompe.orgThis Substrate Reduction Therapy drug could be the first pill taken by mouth to treat Pompe disease. This Substrate Reduction Therapy drug could be the first pill taken by mouth to treat Pompe disease. One of a handful of gene therapy companies with pipelines that include Pompe disease. Today AVROBIO announced a halt to their programs. Amicus Therapeutics, announces the approval of Opfolda (miglustat) capsules, an enzyme stabilizer of cipaglucosidase alfa, by the European Commission for the...
www.pompecanada.comCategory archive page for News.
pompediseasenews.comAro Biotherapeutics has launched a Phase 1b clinical trial for ABX1100, a substrate reduction therapy (SRT). This Pompe Empowerment Workshop welcomes patients and their family from Ontario or the Maritimes, for networking, learning and sharing. This Substrate Reduction Therapy drug could be the first pill taken by mouth to treat Pompe disease. The #Pies4Pompe Challenge is an awareness campaign hosted by Canadian Association of Pompe and driven by community and public participation. … One of a...
www.pompecanada.comMany people receive the plethora of global news items through Google Alerts, Facebook and other Pompe websites, for example "Pompe Disease News". Posts here will be restricted to significant developme
pompe.ukpompe day Latest Breaking News, Pictures, Videos, and Special Reports from The Economic Times. pompe day Blogs, Comments and Archive News on Economictimes.com
economictimes.indiatimes.com